We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TRV:NYSEThe Travelers Companies, Inc. Analysis

Data as of 2026-08-26 - not real-time

$370.63

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

At $370.63, The Travelers Companies, Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. The last 30 days have gained 12.6%. Momentum indicators put RSI at 54.0 (neutral) with MACD reading bearish. Price has been bracketed by support at $358.88 and resistance at $386.95.
Valuation screens as undervalued: a P/E of 10.0 sits below the sector average of 17.1. The 1.35% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 33.7%, a beta of -0.11 and a maximum drawdown of 8.8%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to buy, carrying 7/10 conviction.

Top Market Events

The Travelers Companies Inc TRV reports strong financial performance with significant core income and strategic capital...Travelers TRV is at a 52-week high, but can investors hope for more gains in the future?Let’s dig into the relative performance of Travelers NYSE:TRV and its peers as we unravel the now-completed Q2...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 309.49
  • MACD momentum is negative

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 10.0 versus sector average of 17.1
  • Trading above the 200-day average of 309.49

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • P/E of 10.0 versus sector average of 17.1
  • Profit margin of 17.0% is healthy
  • Return on equity of 26.5%

Key Metrics & Analysis

Financial Health

Revenue Growth0.30%
Profit Margin16.95%
P/E Ratio10.0
ROE26.51%
ROA4.78%
Debt/Equity27.38
P/B Ratio2.3
Op. Cash Flow$11.0B
Free Cash Flow$14.8B
Industry P/E17.1

Technical Analysis

TrendBullish
RSI54.0
Support$358.88
Resistance$386.95
MA 20$372.47
MA 50$355.31
MA 200$309.49
MACDBearish
VolumeDecreasing
Fear & Greed Index94.09

Valuation

Fair Value$898.05
Target Price$360.33
Upside/Downside-2.78%
GradeUndervalued
TypeValue
Dividend Yield1.35%

Risk Assessment

Beta-0.11
Volatility33.72%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.